Diagnostic Products Corp. Primes Pipeline For Imminent AIP Revocation
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic Products Corp. (DPC) expects a series of U.S. product approvals by year-end, pending the removal of an application integrity policy, according to CEO Michael Ziering
You may also be interested in...
Siemens Won $1.86 Bil. DPC Deal By Outbidding Two Other Firms
Siemens' successful bid to acquire Diagnostic Products Corp. earlier this spring was more than a year in the making, according to a recent DPC merger proxy statement
Siemens Won $1.86 Bil. DPC Deal By Outbidding Two Other Firms
Siemens' successful bid to acquire Diagnostic Products Corp. earlier this spring was more than a year in the making, according to a recent DPC merger proxy statement
Diagnostic Products Corp Is Second Device Firm Placed Under AIP In FY 2004
Diagnostic Products Corp says it will hire one or more third-party auditors to assist the firm in resolving an FDA application integrity policy (AIP)